

6. De Vriese AS, Wetzels JF, Glassock R, et al. Therapeutic trials in adult FSGS: lessons learned and the road forward. *Nat Rev Nephrol.* 2021 Sep;17(9):619-630. doi: 10.1038/s41581-021-00427-1.
7. Ahn W, Bomback AS. Approach to Diagnosis and Management of Primary Glomerular Diseases Due to Podocytopathies in Adults: Core Curriculum 2020. *Am J Kidney Dis.* 2020 Jun;75(6):955-964. doi: 10.1053/j.ajkd.2019.12.019.
8. Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. *Kidney Int.* 2021 Oct;100(4):753-779. doi: 10.1016/j.kint.2021.05.015.
9. Osterholt T, Todorova P, Kühne L, et al. Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS. *Sci Rep* 2023 Apr 28;13(1):6980. doi: 10.1038/s41598-023-32576-7.
10. Trachtman H. Emerging drugs for treatment of focal segmental glomerulosclerosis. *Expert Opin Emerg Drugs.* 2020 Sep;25(3):367-375. doi: 10.1080/14728214.2020.1803276.
11. Colucci M, Labbadia R, Vivarelli M, et al. Ofatumumab rescue treatment in post-transplant recurrence of focal segmental glomerulosclerosis. *Pediatric Nephrology* (2020) 35:341–345. <https://doi.org/10.1007/s00467-019-04365-w>
12. Miao J, Krisanapan P, Tangpanithandee S, et al. Efficacy of extracorporeal plasma therapy for adult native kidney patients with Primary FSGS: a Systematic review. *Ren Fail* 2023 Dec;45(1):2176694. doi: 10.1080/0886022X.2023.2176694.
13. Shoji J, Mii A, Terasaki M, Shimizu A. Update on Recurrent Focal Segmental Glomerulosclerosis in Kidney Transplantation. *Nephron* 2020;144 Suppl 1:65-70. doi: 10.1159/000510748.
14. Bai J, Zhang T, Wang Y, et al. Incidence and risk factors for recurrent focal segmental glomerulosclerosis after kidney transplantation: a meta-analysis. *Ren Fail.* 2023 Dec;45(1):2201341. doi: 10.1080/0886022X.2023.2201341.
15. Kienzl-Wagner K, Waldegger S, Schneeberger S. Disease Recurrence-The Sword of Damocles in Kidney Transplantation for Primary Focal Segmental Glomerulosclerosis. *ont Immunol.* 2019 Jul 17;10:1669. doi: 10.3389/fimmu.2019.01669.
16. Garrouste C, Canaud G, Büchler M, et al. Rituximab for Recurrence of Primary Focal Segmental Glomerulosclerosis After Kidney Transplantation: Clinical Outcomes. *Transplantation* 2017 Mar;101(3):649-656.
17. Wang CS, Liverman RS, Garro R, et al. Ofatumumab for the treatment of childhood nephrotic syndrome. *Pediatr Nephrol.* 2017 May;32(5):835-841. doi: 10.1007/s00467-017-3621-8.
18. Bernard J, Bruel A, Allain-Launay E, et al. Ofatumumab in post-transplantation recurrence of a pediatric steroid-resistant idiopathic nephrotic syndrome. *Pediatr Transplant.* 2018 Jun;22(4): e13175. doi: 10.1111/ptr.13175.
19. Al Shamsi HR, Shaheen I, Aziz D. Management of recurrent focal segmental glomerulosclerosis (FSGS) post renal transplantation. *Transplant Rev (Orlando)* 2022 Jan;36(1):100675. doi: 10.1016/j.trre.2021.100675.